Name

CFAR

Alternate names

None

Primary Site

None

Histology

None

Radiation

None

Remarks

None

Drugs for CFAR

Name

Alternate Names

2-FLAMP
2-Fluoro-ARA AMP
2-Fluoro-ara-AMP
Fludara
Fludarabine Monophosphate
Fludarabine Phosphate

Abbreviations

2-FAMP

Category

Chemotherapy

Subcategory

Antimetabolite

NSC Number

312887

Primary Site

CLL
Cutaneous T-cell lymphoma
Leukemia
Non-Hodgkin lymphoma (low grade)

Histology

None

Remarks

FDA approved use on chronic lymphocytic leukemia.

Coding

This drug should be coded

Name

Alternate Names

Campath

Abbreviations

None

Category

Biologic therapy (BRM, immunotherapy)

Subcategory

Targeted therapy

NSC Number

715969

Primary Site

Leukemia
lymphoma

Histology

None

Remarks

JANUARY 2013 IMPORTANT UPDATE: This drug has changed categories. A comprehensive review has been completed and in keeping with the FDA, this drug is to be coded as a Biologic therapy/Immunotherapy agent. Effective with diagnosis date January 1, 2013 forward, code alemtuzumab as BRM/Immunotherapy.For cases diagnosed prior to January 1, 2013 continue coding this drug as chemotherapy.

FDA approved use on chronic lymphocytic leukemia.

Coding

This drug should be coded

Name

Alternate Names

Anti-CD20 monoclonal antibodies
C2B8 monoclonal antibody
IDEC-C2B8
MabThera
Monoclonal antibody IDEC-C2B8
Rituxan

Abbreviations

None

Category

Biologic therapy (BRM, immunotherapy)

Subcategory

Cytostatic monoclonal antibody

NSC Number

687451

Primary Site

Leukemia
NHL

Histology

None

Remarks

JANUARY 2013 IMPORTANT UPDATE: This drug has changed categories. A comprehensive review has been completed and in keeping with the FDA, Rituximab is to be coded as a Biologic therapy/Immunotherapy agent. Effective with diagnosis date January 1, 2013 forward, code Rituximab as BRM/Immunotherapy. For cases diagnosed prior to January 1, 2013 continue coding as chemotherapy.
FDA approved 2/2006 for treatment of diffuse large B-cell, CD-20 positive non-Hodgkin lymphoma.
FDA approved 9/2006 for non-Hodgkin's B-cell lymphoma. Also used to treat autoimmune disorders, hemolytic anemia and ITP.
FDA approved 2/2010 for use in combination with cyclophosphamide and fludarabine in treatment of CLL.
FDA approved for maintenance therapy for previously untreated follicular CD-20 positive B-cell non-Hodgkin lymphoma who acheived response to rituximab in combination with chemotherapy.
June 22, 2017 FDA granted regular approval to the combination of rituximab and hyaluronidase human (RITUXAN HYCELA) for adult patients with follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia.
.

Coding

This drug should be coded

Name

Alternate Names

Asta B 518
B-518
Clafen Claphene
Cyclophosphamid
Cyclophosphan
Cyclophosphane
Cytophosphan
Cytoxan
Endoxan
Endoxana
Enduxan
Genoxal
Neosar
Procytox
Sendoxan
Tymtram
WR-138719

Abbreviations

CP
CPM
CTX
CTY
CYC
Cyclo
CYT
CYTOX
CYTX

Category

Chemotherapy

Subcategory

Alkylating agent

NSC Number

026271
26271

Primary Site

Breast
leukemia
lymphoma
multiple myeloma
neuroblastoma
ovarian cancer
retinoblastoma
soft tissue sarcoma
Wilm's tumor

Histology

None

Remarks

An effective antineoplastic agent and is used for a variety of cancers. FDA approved uses on breast cancer, ovarian carcinoma, leukemia, lymphomas, multiple myeloma, neuroblastma, retinoblastoma, soft tissue sarcoma, Wilm's tumor. Alkylating agent

Coding

This drug should be coded
Glossary